{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:40:56Z","timestamp":1773970856571,"version":"3.50.1"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01257","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T15:12:35Z","timestamp":1573830755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Canine Cancer: Strategies in Experimental Therapeutics"],"prefix":"10.3389","volume":"9","author":[{"given":"Douglas H.","family":"Thamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","article-title":"Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials","volume":"84","author":"Johnson","year":"2001","journal-title":"Br J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2273","article-title":"Translation of new cancer treatments from pet dogs to humans","volume":"8","author":"Paoloni","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1939-1676.2011.0695.x","article-title":"Mortality in North American dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death","volume":"25","author":"Fleming","year":"2011","journal-title":"J Vet Intern Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ilar\/ilu010","article-title":"Naturally occurring cancers in dogs: insights for translational genetics and medicine","volume":"55","author":"Alvarez","year":"2014","journal-title":"ILAR J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1158\/1078-0432.CCR-15-2347","article-title":"Defining the value of a comparative approach to cancer drug development","volume":"22","author":"Leblanc","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"324ps325","DOI":"10.1126\/scitranslmed.aaf0746","article-title":"Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology","volume":"8","author":"Leblanc","year":"2016","journal-title":"Sci Transl Med"},{"key":"B7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-59259-739-0_12","article-title":"Spontaneously occurring tumors in companion animals as models for drug development","volume-title":"Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval","author":"Vail","year":"2004"},{"key":"B8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1740-8261.2001.tb00973.x","article-title":"Toxicity criteria of the veterinary radiation therapy oncology group","volume":"42","author":"Ladue","year":"2001","journal-title":"Vet Radiol Ultrasound"},{"key":"B9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/vco.283","article-title":"Veterinary Cooperative Oncology Group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2013a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"Vail","year":"2010","journal-title":"Vet Comp Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"13","author":"Nguyen","year":"2015","journal-title":"Vet Comp Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/bjc.1990.411","article-title":"Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours","volume":"62","author":"Cline","year":"1990","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0360-3016(93)90465-8","article-title":"The relationship between proliferative and oxygenation status in spontaneous canine tumors","volume":"27","author":"Zeman","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/0360-3016(94)90113-9","article-title":"Distribution of the hypoxia marker CCI-103F in canine tumors","volume":"28","author":"Cline","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/02841869509093987","article-title":"Distribution of hypoxia and proliferation associated markers in spontaneous canine tumors","volume":"34","author":"Raleigh","year":"1995","journal-title":"Acta Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0360-3016(96)00559-7","article-title":"Quantification of CCI-103F labeling heterogeneity in canine solid tumors","volume":"37","author":"Cline","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0167-8140(97)01931-2","article-title":"Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning","volume":"44","author":"Thrall","year":"1997","journal-title":"Radiother Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00003086-200104000-00034","article-title":"Interstitial fluid pressure and blood flow in canine osteosarcoma and other tumors","author":"Zachos","year":"2001","journal-title":"Clin Orthop Relat Res"},{"key":"B19","first-page":"1734","article-title":"Limb-sparing treatment for osteosarcoma in dogs","volume":"195","author":"Larue","year":"1989","journal-title":"J Am Vet Med Assoc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/0360-3016(90)90308-7","article-title":"Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay","volume":"18","author":"Thrall","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1002\/1097-0142(19930415)71:8<2484::AID-CNCR2820710810>3.0.CO;2-D","article-title":"Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma","volume":"71","author":"Withrow","year":"1993","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ilar.51.3.208","article-title":"Cross talk from pets to people: translational osteosarcoma treatments","volume":"51","author":"Withrow","year":"2010","journal-title":"ILAR J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1245\/ASO.2005.01.011","article-title":"Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma","volume":"12","author":"Lascelles","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1245\/s10434-007-9483-8","article-title":"Post operative infection and increased survival in osteosarcoma patients: are they associated?","volume":"14","author":"Jeys","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00262-009-0755-y","article-title":"Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses","volume":"59","author":"Sottnik","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1148\/116.1.175","article-title":"Endothelial repair of radiation damage following beta irradiation","volume":"116","author":"Gillette","year":"1975","journal-title":"Radiology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0360-3016(79)91213-6","article-title":"Repair of sublethal radiation damage by capillaries","volume":"5","author":"Fike","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2307\/3575726","article-title":"Radiation response of the canine cardiovascular system","volume":"90","author":"Gavin","year":"1982","journal-title":"Radiat Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/0360-3016(85)90089-6","article-title":"Isoeffect curves for radiation-induced cardiomyopathy in the dog","volume":"11","author":"Gillette","year":"1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2307\/3576600","article-title":"The pathogenesis of radiation nephropathy in the dog","volume":"104","author":"Hoopes","year":"1985","journal-title":"Radiat Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/0360-3016(87)90164-7","article-title":"Late radiation response of the canine trachea with change in dose per fraction","volume":"13","author":"Powers","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/1097-0142(19880915)62:6<1091::AID-CNCR2820620611>3.0.CO;2-A","article-title":"Exocrine pancreatic function following intraoperative irradiation of the canine pancreas","volume":"62","author":"Ahmadu-Suka","year":"1988","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0360-3016(90)90540-Z","article-title":"Radiation-induced ocular injury in the dog: a histological study","volume":"19","author":"Ching","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2307\/3577979","article-title":"Early radiation response of the canine heart and lung","volume":"125","author":"Gillette","year":"1991","journal-title":"Radiat Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0360-3016(91)90058-C","article-title":"Muscle injury following experimental intraoperative irradiation","volume":"20","author":"Powers","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/02656739209021786","article-title":"Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia: a randomized phase II study","volume":"8","author":"Gillette","year":"1992","journal-title":"Int J Hyperthermia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0360-3016(89)90019-9","article-title":"Response of the canine lung to fractionated irradiation: pathologic changes and isoeffect curves","volume":"16","author":"McChesney","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0360-3016(03)00090-7","article-title":"Image guidance for precise conformal radiotherapy","volume":"56","author":"Mackie","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.ijrobp.2004.08.016","article-title":"The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes","volume":"60","author":"Forrest","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/02656730600836386","article-title":"Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas","volume":"22","author":"Thrall","year":"2006","journal-title":"Int J Hyperthermia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-10-2583","article-title":"Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics","volume":"17","author":"Chi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3109\/02656736.2012.689087","article-title":"Thermal dose fractionation affects tumour physiological response","volume":"28","author":"Thrall","year":"2012","journal-title":"Int J Hyperthermia"},{"key":"B43","first-page":"2653","article-title":"Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model","volume":"5","author":"Hershey","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/jamp.2009.0773","article-title":"Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs","volume":"23","author":"Rodriguez","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1409::AID-CNCR19>3.0.CO;2-3","article-title":"Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases","volume":"79","author":"Khanna","year":"1997","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"249ra111","DOI":"10.1126\/scitranslmed.3008982","article-title":"Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses","volume":"6","author":"Roberts","year":"2014","journal-title":"Sci Transl Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1172\/JCI510","article-title":"In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma","volume":"101","author":"Dow","year":"1998","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00262-003-0387-6","article-title":"Intralesional lipid-complexed cytokine\/superantigen immunogene therapy for spontaneous canine tumors","volume":"52","author":"Thamm","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"B49","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.rvsc.2010.12.012","article-title":"Cytokine-enhanced vaccine and interferon-beta plus suicide gene as combined therapy for spontaneous canine sarcomas","volume":"91","author":"Finocchiaro","year":"2011","journal-title":"Res Vet Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CJI.0b013e31829d8a1b","article-title":"Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma","volume":"36","author":"Westberg","year":"2013","journal-title":"J Immunother"},{"key":"B51","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3109\/02656739109056456","article-title":"Localized thermo-cisplatin therapy: a pilot study in spontaneous canine and feline tumours","volume":"7","author":"Theon","year":"1991","journal-title":"Int J Hyperthermia"},{"key":"B52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2460\/javma.1994.204.02.229","article-title":"Intralesional implant for treatment of primary oral malignant melanoma in dogs","volume":"204","author":"Kitchell","year":"1994","journal-title":"J Am Vet Med Assoc"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/0360-3016(94)90398-0","article-title":"Concurrent irradiation and intratumoral chemotherapy with cisplatin: a pilot study in dogs with spontaneous tumors","volume":"29","author":"Theon","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/0959-8049(95)00446-7","article-title":"Intralesional sustained-release chemotherapy with therapeutic implants for treatment of canine sun-induced squamous cell carcinoma","author":"Kitchell","year":"1995","journal-title":"Eur J Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2460\/ajvr.73.12.1969","article-title":"Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas","volume":"73","author":"Venable","year":"2012","journal-title":"Am J Vet Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0301-472X(98)00075-7","article-title":"Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit","volume":"27","author":"London","year":"1999","journal-title":"Exp Hematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1541-7786.MCR-14-0689","article-title":"Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer\u2013evidence for a relevant model system and urine-based diagnostic test","volume":"13","author":"Decker","year":"2015","journal-title":"Mol Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/vco.12275","article-title":"Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma","volume":"15","author":"Mochizuki","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/blood-2001-12-0350","article-title":"Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors","volume":"100","author":"Liao","year":"2002","journal-title":"Blood"},{"key":"B60","first-page":"2755","article-title":"Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies","volume":"9","author":"London","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B61","first-page":"5729","article-title":"Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors","volume":"9","author":"Pryer","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e87585","DOI":"10.1371\/journal.pone.0087585","article-title":"Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study","volume":"9","author":"London","year":"2014","journal-title":"PLoS ONE"},{"key":"B64","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e4972","DOI":"10.1371\/journal.pone.0004972","article-title":"Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature","volume":"4","author":"Paoloni","year":"2009","journal-title":"PLoS ONE"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-04-2510","article-title":"Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation","volume":"11","author":"Thamm","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JCO.20.1.142","article-title":"Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma","volume":"20","author":"Toso","year":"2002","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-06-0226","article-title":"Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors","volume":"12","author":"Hauck","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.4161\/auto.29165","article-title":"Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma","volume":"10","author":"Barnard","year":"2014","journal-title":"Autophagy"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1158\/1078-0432.CCR-18-1498","article-title":"NCI Comparative Oncology Program testing of non-camptothecin indenoisoquinoline topoisomerase i inhibitors in naturally occurring canine lymphoma","volume":"24","author":"Burton","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B71","first-page":"1595","article-title":"Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin","volume":"1","author":"Kurzman","year":"1995","journal-title":"Clin Cancer Res"},{"key":"B72","first-page":"1165","article-title":"Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial","volume":"1","author":"Vail","year":"1995","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/cbr.1999.14.121","article-title":"In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells","volume":"14","author":"Kurzman","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2005.06.031","article-title":"Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and\/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate","volume":"23","author":"Meyers","year":"2005","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00280-002-0469-8","article-title":"STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial","volume":"50","author":"Vail","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1158\/1535-7163.MCT-16-0637","article-title":"Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR","volume":"16","author":"Borgatti","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.vetimm.2009.04.020","article-title":"Evaluation of immunological status in tumor-bearing dogs","volume":"132","author":"Itoh","year":"2009","journal-title":"Vet Immunol Immunopathol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.vetimm.2012.12.010","article-title":"Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer","volume":"152","author":"De Andres","year":"2013","journal-title":"Vet Immunol Immunopathol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.yexcr.2014.02.020","article-title":"Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment","volume":"323","author":"Kim","year":"2014","journal-title":"Exp Cell Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.yexcr.2017.07.011","article-title":"Exosomes from osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells","volume":"358","author":"Troyer","year":"2017","journal-title":"Exp Cell Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.vetimm.2006.12.002","article-title":"Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer","volume":"116","author":"Biller","year":"2007","journal-title":"Vet Immunol Immunopathol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/j.1939-1676.2009.0333.x","article-title":"Changes in regulatory T cells in dogs with cancer and associations with tumor type","volume":"23","author":"O'Neill","year":"2009","journal-title":"J Vet Intern Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1939-1676.2010.0557.x","article-title":"Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma","volume":"24","author":"Biller","year":"2010","journal-title":"J Vet Intern Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e33274","DOI":"10.1371\/journal.pone.0033274","article-title":"Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer","volume":"7","author":"Goulart","year":"2012","journal-title":"PLoS ONE"},{"key":"B85","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1746-6148-8-209","article-title":"Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs","volume":"8","author":"Sherger","year":"2012","journal-title":"BMC Vet Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41598-019-40285-3","article-title":"Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells","volume":"9","author":"Goulart","year":"2019","journal-title":"Sci Rep"},{"key":"B87","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12917-015-0473-y","article-title":"Canine mammary cancer cells direct macrophages toward an intermediate activation state between M1\/M2","volume":"11","author":"Beirao","year":"2015","journal-title":"BMC Vet Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/vco.12272","article-title":"Role of monocyte recruitment in hemangiosarcoma metastasis in dogs","volume":"15","author":"Regan","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.tvjl.2018.02.016","article-title":"Tumour-associated macrophages: relation with progression and invasiveness, and assessment of M1\/M2 macrophages in canine mammary tumours","volume":"234","author":"Monteiro","year":"2018","journal-title":"Vet J"},{"key":"B90","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/0300985817750457","article-title":"CD204-expressing tumor-associated macrophages are associated with malignant, high-grade, and hormone receptor-negative canine mammary gland tumors","volume":"55","author":"Seung","year":"2018","journal-title":"Vet Pathol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e98415","DOI":"10.1371\/journal.pone.0098415","article-title":"Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade","volume":"9","author":"Maekawa","year":"2014","journal-title":"PLoS ONE"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e0157176","DOI":"10.1371\/journal.pone.0157176","article-title":"Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma","volume":"11","author":"Maekawa","year":"2016","journal-title":"PLoS ONE"},{"key":"B93","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2460\/ajvr.79.6.643","article-title":"Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma","volume":"79","author":"Ambrosius","year":"2018","journal-title":"Am J Vet Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/vco.12386","article-title":"Checkpoint molecule expression by B and T cell lymphomas in dogs","volume":"16","author":"Hartley","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.dld.2018.11.001","article-title":"Frequency and risk factors for liver disease following pancreatitis: a population-based cohort study","volume":"51","author":"Chand","year":"2019","journal-title":"Dig Liver Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0014-2964(77)90227-4","article-title":"The effect of BCG on in vitro immune reactivity and clinical course in dogs treated surgically for osteosarcoma","volume":"13","author":"Bech-Nielsen","year":"1977","journal-title":"Eur J Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/0014-2964(78)90104-4","article-title":"Intravenous BCG therapy of mammary carcinoma in bitches after surgical excision of the primary tumour","volume":"14","author":"Bostock","year":"1978","journal-title":"Eur J Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/1097-0142(19820415)49:8<1613::AID-CNCR2820490814>3.0.CO;2-R","article-title":"Canine osteogenic sarcoma treated by amputation and MER: an adverse effect of splenectomy on survival","volume":"49","author":"Meyer","year":"1982","journal-title":"Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/BF00199160","article-title":"Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy","volume":"15","author":"Parodi","year":"1983","journal-title":"Cancer Immunol Immunother"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2460\/ajvr.68.11.1246","article-title":"Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs","volume":"68","author":"Henry","year":"2007","journal-title":"Am J Vet Res"},{"key":"B101","first-page":"4249","article-title":"Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor","volume":"5","author":"Macewen","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B102","first-page":"233","article-title":"Preclinical study of sequential tumor necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms","volume":"51","author":"Moore","year":"1991","journal-title":"Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1158\/0008-5472.CAN-10-0600","article-title":"IFN\u03b3 markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models","volume":"70","author":"Mito","year":"2010","journal-title":"Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1476-5829.2010.00234.x","article-title":"Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma","volume":"9","author":"Henson","year":"2011","journal-title":"Vet Comp Oncol"},{"key":"B105","first-page":"931","article-title":"Palliative intralesional interleukin-2 treatment in dogs with urinary bladder and urethral carcinomas","volume":"26","author":"Konietschke","year":"2012","journal-title":"In Vivo"},{"key":"B106","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1746-6148-9-155","article-title":"The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study","volume":"9","author":"Haagsman","year":"2013","journal-title":"BMC Vet Res"},{"key":"B107","first-page":"161","article-title":"Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs","volume":"33","author":"Ziekman","year":"2013","journal-title":"Anticancer Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/hum.2014.130","article-title":"Cytokine-enhanced vaccine and interferon-beta plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma","volume":"26","author":"Finocchiaro","year":"2015","journal-title":"Hum Gene Ther"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1158\/1078-0432.CCR-15-3026","article-title":"Blocking indolamine-2,3-dioxygenase rebound immune suppression boosts antitumor effects of radio-immunotherapy in murine models and spontaneous canine malignancies","volume":"22","author":"Monjazeb","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/vco.12255","article-title":"Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer","volume":"15","author":"Cicchelero","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e0129954","DOI":"10.1371\/journal.pone.0129954","article-title":"Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma","volume":"10","author":"Paoloni","year":"2015","journal-title":"PLoS ONE"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-16-2152","article-title":"KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells","volume":"23","author":"London","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1038\/s41598-017-09444-2","article-title":"A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma","volume":"7","author":"Maekawa","year":"2017","journal-title":"Sci Rep"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1089\/hum.1998.9.13-1851","article-title":"Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer","volume":"9","author":"Hogge","year":"1998","journal-title":"Hum Gene Ther"},{"key":"B115","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1476-5829.2007.00128.x","article-title":"Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma","volume":"5","author":"Turek","year":"2007","journal-title":"Vet Comp Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00262-010-0921-2","article-title":"An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine","volume":"60","author":"Bird","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e24167","DOI":"10.1371\/journal.pone.0024167","article-title":"CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma","volume":"6","author":"Sorenmo","year":"2011","journal-title":"PLoS ONE"},{"key":"B118","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/1078-0432.CCR-13-2283","article-title":"Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma","volume":"20","author":"Marconato","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1939-1676.2007.tb02936.x","article-title":"Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma","volume":"21","author":"U'Ren","year":"2007","journal-title":"J Vet Intern Med"},{"key":"B120","first-page":"1284","article-title":"Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial","volume":"9","author":"Bergman","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1016\/j.vaccine.2005.08.027","article-title":"Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center","volume":"24","author":"Bergman","year":"2006","journal-title":"Vaccine"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00262-007-0282-7","article-title":"Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma","volume":"56","author":"Kamstock","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"B123","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1089\/hum.2013.112","article-title":"Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma","volume":"24","author":"Gavazza","year":"2013","journal-title":"Hum Gene Ther"},{"key":"B124","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-16-0088","article-title":"Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma","volume":"22","author":"Mason","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.vetimm.2016.06.007","article-title":"Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection","volume":"177","author":"Mie","year":"2016","journal-title":"Vet Immunol Immunopathol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/srep00249","article-title":"Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy","volume":"2","author":"O'Connor","year":"2012","journal-title":"Sci Rep"},{"key":"B127","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/vco.12361","article-title":"Oncolytic reovirus therapy: pilot study in dogs with spontaneously occurring tumours","volume":"16","author":"Hwang","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/1535-7163.MCT-17-0432","article-title":"Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer","volume":"17","author":"Naik","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/mt.2016.146","article-title":"Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B Cell lymphoma","volume":"24","author":"Panjwani","year":"2016","journal-title":"Mol Ther"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1089\/10430340050032447","article-title":"A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma","volume":"11","author":"Walsh","year":"2000","journal-title":"Univ Colorado Cancer Center Clinical Trial Hum Gene Ther"},{"key":"B131","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2051-1426-1-20","article-title":"Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma","volume":"1","author":"Yuan","year":"2013","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01257\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:50:13Z","timestamp":1722041413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01257\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":131,"alternative-id":["10.3389\/fonc.2019.01257"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01257","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"article-number":"1257"}}